Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -40

Novo Nordisk Faces a September Reckoning as Oral Wegovy’s China Hopes Collide With Analyst Doubts

AI-generated analysis

📉 Novo Nordisk shares are trading near multi-month lows, down roughly 27 percent from its 52-week high as investor sentiment turns cautious ahead of the September 21 capital markets day.

📉 Deutsche Bank downgraded the stock to Sell with a price target cut to DKK 265, citing lackluster Q2 performance and fundamental doubts about the company's growth trajectory.

💊 Eli Lilly has launched its oral weight-loss drug Foundayo in the UK while receiving FDA approval for Mounjaro's cardiovascular risk reduction label, intensifying competition for Novo Nordisk's GLP-1 portfolio.

💸 Novo Nordisk agreed to cut US prices for Wegovy and Ozempic via Medicare, Medicaid, and TrumpRx channels to $350 per month, a move expected to compress profitability in its primary growth engine.

🇨🇳 China's drug regulator has accepted the filing for oral Wegovy, offering a potential long-term expansion pathway into the world's second-largest pharmaceutical market with a vast patient population.

⚖️ Analyst sentiment remains divided, with Citi maintaining a Sell rating due to slowing prescription trends while JPMorgan holds a Neutral rating, citing the upcoming oral formulation rollout as a potential catalyst.

Bullish Signals
  • China's drug regulator has accepted the filing for oral Wegovy, opening access to the world's second-largest pharmaceutical market and providing a long-term expansion pathway to offset growth concerns in Europe and the US.
  • The company is launching its oral formulation of Wegovy in Germany while awaiting European Commission approval, creating a two-pronged push for its oral product across key markets.
Risk Factors
  • Deutsche Bank downgraded the stock to Sell and cut its price target to DKK 265, citing lackluster second-quarter results, cautious forward guidance, and softer-than-expected Wegovy sales.
  • Novo Nordisk agreed to significant price cuts for US semaglutide products via Medicare, Medicaid, and TrumpRx channels, a move that will inevitably compress profitability in its primary growth engine.
  • Rival Eli Lilly has launched its oral weight-loss drug Foundayo and received FDA approval for Mounjaro's cardiovascular risk reduction label, creating structural headwinds that could weigh on Novo Nordisk's growth prospects.
  • Citi reaffirmed its Sell rating with a price target of DKK 265, pointing to a slowdown in GLP-1 prescription trends as a key concern for the company's near-term outlook.
Full Analysis
Novo Nordisk faces a critical inflection point ahead of its September 21 capital markets day, with shares trading near multi-month lows and under pressure from bearish analyst downgrades. Deutsche Bank recently downgraded the stock to Sell, citing lackluster second-quarter results, cautious guidance, and softer-than-expected Wegovy sales. The company's stock has declined roughly 27 percent from its 52-week high, reflecting growing investor skepticism regarding its growth trajectory amidst intensifying competition. The bearish outlook is driven by structural headwinds in both the United States and Europe. In the US, Novo Nordisk agreed to significant price cuts for its semaglutide products, including Wegovy and Ozempic, via new channels like TrumpRx, which will compress profitability in its primary growth engine. Simultaneously, rival Eli Lilly has launched its own oral weight-loss drug, Foundayo, while receiving FDA approval for Mounjaro to reduce cardiovascular risk, sharpening the competitive landscape in the GLP-1 arena. Despite these challenges, China emerges as a potential counterweight to offset growth concerns from Western markets. The Chinese drug regulator has accepted Novo Nordisk's filing for the oral version of Wegovy, opening access to the world's second-largest pharmaceutical market with a massive patient population. This development provides a long-term expansion pathway that could partially mitigate the impact of pricing concessions and rivalry in Europe and the US, though approval timelines remain undisclosed.